A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Wake Forest School of Medicine
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center.
ClinicalTrials.gov Identifier:
NCT00587067
First received: December 21, 2007
Last updated: December 19, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2015
  Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)